Millie
your market intelligence analyst
Search Results
135 results
Your search is now limited to «Clinical Trials» expert search.
Johnson & Johnson 07/23/2019 11:00
Additional Vaccine Studies at IAS Janssen’s HIV vaccine presentations at IAS will also include the latest long-term findings from the Phase 1/2a APPROACH study, which examined two regimens of a mosaic-based viral vector with varying doses of the Clade ...
More from Johnson & Johnson:
PharmiWeb.com 07/22/2019 22:23
ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV.
More from PharmiWeb.com:
Business Wire 07/22/2019 07:00
Topline data from the trial are expected in the first quarter of 2020.
More from Business Wire:
Paula Williamson has received income from AbbVie (AbbVie Inc., IL, USA) related to fees for the preparation of a clinical study report for the randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis-associated uveitis (SYCAMORE.
ClinicalTrials.gov 07/17/2019 07:53
Condition : HIV-1-infection Interventions : Drug: dolutegravir; Drug: atazanavir boosted with ritonavir; Drug: tenofovir + lamivudine +efavirenz; Drug: Lamivudine Sponsors : French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); Mylan Laboratories Not yet recruiting.
More from ClinicalTrials.gov:
ENDPOINTS 07/12/2019 10:53
Abivax now has sufficient time and resources to leverage maximum value in ongoing partnering discussions for ABX464, while also providing funding to achieve important value-creating milestones in three phase 2 trials of ABX464 in ulcerative colitis, rheumatoid arthritis and Crohn’s disease and one phase 1/2 trial of ABX196 in liver cancer,” CEO Hartmut Ehrlich said in a statement.
GlobeNewswire 07/11/2019 16:01
Based on the magnitude of response shown in pre-clinical models, HOOKIPA believes that HB-201 has the potential to induce levels of CD8+ T cells that were previously only attainable with adoptive cell therapies.
More from GlobeNewswire:
ViiV Healthcare’s phase 3 study of dolutegravir plus lamivudine meets primary endpoint.
More from Pharmaceutical Business Review:
BioNewsFeeds 07/10/2019 11:58
The Phase 1/2 trial (NCT03993678) assessing these two approaches, used in combination, will take place at three clinical sites in Switzerland, and is divided in two parts.
More from BioNewsFeeds:
Benzinga 07/10/2019 10:15
The company said it will present full results from the study at the 10th International AIDS Society Conference on HIV Science July 21-24 in Mexico City.
More from Benzinga:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications